Fibroblast Growth Factor-23 and Hypophosphatemia in Chronic Obstructive Pulmonary Disease Patients

Impaired serum phosphate levels may contribute to respiratory muscle weakness that further negatively impacts Chronic Obstructive Pulmonary Disease (COPD) patients. Recently, Fibroblast Growth Factor 23 (FGF-23) has been shown to play an important role in the regulation of body phosphate. The current study includes 2 groups: 70 COPD patients and 34 control subjects. Blood samples were taken for a panel of routine lab tests. FGF-23 was measured using a commercially available ELISA kit. Plasma FGF-23 levels were significantly higher in the patient group compared to the control group (P=0.000). Tubular maximum absorption of phosphate was significantly reduced in COPD patients compared to the control group (P=0.04). Plasma FGF-23 negatively correlated with FEV1 and serum albumin. Elevated plasma FGF-23 levels found in COPD patients correlated with disease severity and may represent an additional factor causing low serum phosphate. Poremećeni nivoi fosfata u serumu mogu dodatno oslabiti respiratorne mišiće, što negativno utiče na pacijente sa hroničnom opstruktivnom bolešću pluća (HOBP). Nedavno je pokazano da faktor rasta fibroblasta 23 (FGF-23) ima važnu ulogu u regulisanju nivoa fosfata u telu. Ova studija obuhvatila je dve grupe: 70 pacijenata sa HOBP i 34 kontrolna subjekta. Uzeti su uzorci krvi za panel rutinskih laboratorijskih testova. FGF-23 meren je pomoću komercijalnih ELISA testova. Nivoi FGF-23 u plazmi bili su značajno viši u grupi pacijenata nego u kontrolnoj grupi (P=0,000). Maksimalna tubularna apsorpcija fosfata bila je značajno snižena kod pacijenata sa HOBP u poređenju sa kontrolnom grupom (P=0,04). FGF-23 u plazmi bio je u negativnoj korelaciji sa FEV1 i albuminom u serumu. Povišeni nivoi FGF-23 u plazmi kod obolelih od HOBP u korelaciji su sa stadijumom oboljenja i možda predstavljaju dodatni faktor odgovoran za nizak nivo fosfata u serumu.